Moreover, newer treatments like SGLT2 inhibitors, GLP-1 receptor agonists, and advancements in intravascular imaging show promise in reducing DM and CVD-related morbidity and mortality [8,[19], [20], [21], [22]]. This evidence concerns the gene SLC5A2 and diabetes mellitus.